{"id":9714,"date":"2026-10-29T16:59:21","date_gmt":"2026-10-29T11:29:21","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/pplpharma-share-price-today-2026-10-29\/"},"modified":"2026-10-29T16:59:23","modified_gmt":"2026-10-29T11:29:23","slug":"pplpharma-share-price-today-2026-10-29","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/pplpharma-share-price-today-2026-10-29\/","title":{"rendered":"Piramal Pharma Share Price Today: Rises 16.04% in 2 Trading Sessions | 29 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: PPLPHARMA<\/strong> \u00b7 29 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b9230.60<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>-0.95%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b9239.22 \/ \u20b9225.68<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b9232.80<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>2.56 crore<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>29 October 2026 \u00b7 03:25 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Piramal Pharma has risen 16.04% over 2 trading sessions; today&#x27;s move is -0.95%.<\/li>\n<li>Piramal Pharma reported consolidated financial results for the quarter and half year ended September 30, 2026, showing revenue from operations of \u20b92,617 crores in Q2 (up 28% year-on-year) and \u20b94,887 crores in H1 (up 23% year-on-year). EBITDA for Q2 jumped 72% year-on-year to \u20b9385 crores with margins expanding over 350 basis points to 14.7%, driven by strong performance across CDMO, Complex Hospital Generics, and Consumer Healthcare. Backed by this robust first-half performance, management upgraded its FY27 revenue growth outlook to 19%-20% with higher profitability.<\/li>\n<li>Trading volume was 3.16 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Piramal Pharma share price: 16.04% rise over 2 trading sessions<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Piramal Pharma Ltd. (PPLPHARMA) traded down 0.95% on Wednesday, closing at \u20b9230.60 after moving between an intraday high of \u20b9239.22 and a low of \u20b9225.68.<\/p>\n<p class=\"wt-copy\">While the broader Indian equity market advanced, with the Nifty rising 1.05% and the Nifty Pharma sector index gaining 0.64%, Piramal Pharma experienced mild profit-taking. Wednesday&#x27;s pullback follows a sharp multi-day rally that drove strong prior returns of 17.15% over the last one trading day, 19.28% over the past two sessions, and 18.26% over the preceding five trading days.<\/p>\n<p class=\"wt-copy\">Company disclosures provide ongoing context regarding business performance, highlighted by the release of consolidated financial results for the quarter and half year ended September 30, 2026. Management reported robust H1 FY27 revenue of \u20b94,887 crores, representing a 23% year-on-year increase, alongside a 72% surge in EBITDA to \u20b9669 crores and an upgraded full-year outlook. While these fundamental milestones supported recent upward momentum, Wednesday&#x27;s price action appears largely consistent with consolidation and normal profit-taking following a steep prior advance.<\/p>\n<p class=\"wt-copy\">2.56 crore shares traded by 29 October 2026 \u00b7 03:25 PM IST. This compares with a 20-day average daily volume of 80.95 lakh shares (3.16 times). The five-day average daily volume was 2.55 crore shares. Separately, the NSE report for 28 October 2026 showed 1.86 crore shares delivered, representing 15.74% of that day\u2019s traded volume. The same report recorded 710,974 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>profit-taking and consolidation after strong multi-day rally<\/strong><\/p>\n<p class=\"wt-copy\">The stock retreated slightly by 0.95% despite heavy cash volume reaching 3.16 times its 20-day average. This move follows an aggressive multi-day surge, including a 17.15% gain in the prior session, pointing to natural profit-taking and technical consolidation after sharp recent outperformance.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Q2 and H1 FY27 Financial Results &amp; Guidance Upgrade<\/div>\n<div class=\"wt-card-date\">27 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Piramal Pharma reported consolidated financial results for the quarter and half year ended September 30, 2026, showing revenue from operations of \u20b92,617 crores in Q2 (up 28% year-on-year) and \u20b94,887 crores in H1 (up 23% year-on-year). EBITDA for Q2 jumped 72% year-on-year to \u20b9385 crores with margins expanding over 350 basis points to 14.7%, driven by strong performance across CDMO, Complex Hospital Generics, and Consumer Healthcare. Backed by this robust first-half performance, management upgraded its FY27 revenue growth outlook to 19%-20% with higher profitability.<\/p>\n<p class=\"wt-copy\">It establishes strong underlying operational momentum, improved capacity utilization, and upgraded growth expectations across all core business segments.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Expiry of Commercial Arrangement with Bayer Pharmaceuticals<\/div>\n<div class=\"wt-card-date\">1 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company announced that its commercial arrangement providing sales and distribution support services to Bayer Pharmaceuticals Private Limited will conclude upon its natural expiry on December 31, 2026, and will not be renewed. Piramal Pharma noted that revenue from this commission-based arrangement accounts for less than 5% of consolidated revenue and does not expect the non-renewal to materially impact its profitability or financial position.<\/p>\n<p class=\"wt-copy\">It clarifies the financial impact of an ending distribution partnership, assuring investors that the transition will not materially affect earnings or guidance.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/PIRAMALPHARMA_30092026201259_SEIntimationAppointmentofCTO.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Completion of Controlling Stake Acquisition in Yapan Bio<\/div>\n<div class=\"wt-card-date\">18 August 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Piramal Pharma completed its previously announced transaction to acquire a controlling equity stake in Yapan Bio Private Limited, exercising its call option to strengthen its biologics and advanced therapeutic capabilities. This integration expands the company&#x27;s specialized service offerings within the CDMO segment, particularly in high-growth biologics and process development.<\/p>\n<p class=\"wt-copy\">It enhances the company&#x27;s advanced technological capabilities in biologics, supporting long-term expansion within the high-value CDMO landscape.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Priyankamehta_18082026113757_SEDisclosure_CompletionofacquistioninYapan.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Press Release<\/div>\n<div class=\"wt-card-date\">28 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 27, 2026, titled &quot;Piramal Pharma Limited Announces Results for Q2 and H1 FY2&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Priyankamehta_27102026210401_PRandIRIntimation27Oct26sd.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Outcome of Board Meeting<\/div>\n<div class=\"wt-card-date\">28 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Priyankamehta_27102026210048_Outcome_of_BM_271026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">34.80%<\/div>\n<div class=\"wt-note\">34.80% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">13.65%<\/div>\n<div class=\"wt-note\">12.52% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">28.09%<\/div>\n<div class=\"wt-note\">27.09% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742857_21102026032628_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 12.71% on 30 September 2026. This compares with 13.18% on 30 June 2026, a change of -0.47 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 27 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">7.52 crore shares \u00b7 5.65%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Nippon Life India Trustee Ltd-A\/C Nippon India Small Cap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.08 crore shares \u00b7 1.56%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742857_21102026032628_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution of upgraded FY27 guidance targeting 19%-20% revenue growth<\/li>\n<li>Integration progress and revenue contribution from the Kenalog and Yapan Bio acquisitions<\/li>\n<li>Sustained order inflows and RFP activity within the CDMO segment<\/li>\n<li>Cash volume and delivery percentage trends relative to the 20-day average volume baseline<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/pplpharma-share-price-today-2026-10-28\/\">Piramal Pharma Share Price Today: Rises 18.36% in 2 Trading Sessions | 28 October 2026 \u2014 28 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/pplpharma\/\">More Piramal Pharma news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Piramal Pharma company news?<\/h3>\n<p class=\"wt-copy\">Piramal Pharma reported consolidated financial results for the quarter and half year ended September 30, 2026, showing revenue from operations of \u20b92,617 crores in Q2 (up 28% year-on-year) and \u20b94,887 crores in H1 (up 23% year-on-year). EBITDA for Q2 jumped 72% year-on-year to \u20b9385 crores with margins expanding over 350 basis points to 14.7%, driven by strong performance across CDMO, Complex Hospital Generics, and Consumer Healthcare. Backed by this robust first-half performance, management upgraded its FY27 revenue growth outlook to 19%-20% with higher profitability.<\/p>\n<h3>How strong was Piramal Pharma\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">2.56 crore shares traded, 3.16 times the 20-day average daily volume. The price and volume data are dated 29 October 2026 \u00b7 03:25 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/pplpharma-share-price-today-2026-10-29\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/pplpharma-share-price-today-2026-10-29\/\"}, \"headline\": \"Piramal Pharma Share Price Today: Rises 16.04% in 2 Trading Sessions | 29 October 2026\", \"description\": \"Piramal Pharma has risen 16.04% over 2 trading sessions. Today it is 0.95% lower at \u20b9230.60. See price context, volume and key company developments.\", \"datePublished\": \"2026-10-29T16:59:10.894960+05:30\", \"dateModified\": \"2026-10-29T16:59:10.894960+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Piramal Pharma\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"PPLPHARMA\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/pplpharma-company-news-2026-10-29.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Press Release\",\"summary\":\"a press release dated October 27, 2026, titled \\\"Piramal Pharma Limited Announces Results for Q2 and H1 FY2\\\".\",\"source\":\"NSE\",\"published\":\"27-Oct-2026 21:04:21\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Priyankamehta_27102026210401_PRandIRIntimation27Oct26sd.pdf\"},{\"title\":\"Outcome of Board Meeting\",\"summary\":\"Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"source\":\"NSE\",\"published\":\"27-Oct-2026 21:02:02\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Priyankamehta_27102026210048_Outcome_of_BM_271026.pdf\"}],\"recent_news\":[{\"summary\":\"a press release dated October 27, 2026, titled \\\"Piramal Pharma Limited Announces Results for Q2 and H1 FY2\\\".\",\"category\":\"Press Release\",\"date\":\"27-Oct-2026 21:04:21\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Priyankamehta_27102026210401_PRandIRIntimation27Oct26sd.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"27-Oct-2026 21:02:02\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Priyankamehta_27102026210048_Outcome_of_BM_271026.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"The exchange sought clarification from the company regarding a recent media report. Such a request is a verification step and does not by itself confirm the reported issue.\",\"category\":\"News Verification\",\"date\":\"01-Oct-2026 19:14:49\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/PIRAMALPHARMA_01102026105231_Responseletter.pdf\",\"headline\":\"Exchange clarification on media report\",\"impact\":\"This can influence near-term sentiment while investors wait for the company's response, but it becomes materially important only if the company confirms a financial or operational impact.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"'Exercise of call option for acquisition of additional equity stake in Yapan Bio PrivateLimited'.\",\"category\":\"Updates\",\"date\":\"10-Aug-2026 18:09:03\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Priyankamehta_10082026180821_SE_Disclosure_Call_option_exercise_-_Yapan.pdf\",\"headline\":\"Investment \/ acquisition update\",\"impact\":\"The transaction can affect growth strategy, capital allocation or market access. Investors should consider the size of the investment, ownership acquired and expected returns.\",\"importance_score\":4,\"completeness_score\":3}],\"promoter_pledge\":{\"summary\":\"The promoter\/promoter-group disclosure states that the shares covered by the filing were free from encumbrance.\",\"events\":[{\"summary\":\"Ajay G. Piramal Date: 6th April, 2026 To, To, BSE Limited National Stock Exchange of India Limited Mumbai Mumbai BSE Script code: 543635 NSE Symbol: PPLPHARMA Re.: Piramal Pharma Limited Sub: Declaration under Regulation 31(4) of SEBI (SAST) Regulations, 2011 from the Promoter Pursuant to the Regulation 31(4) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (\u201cSEBI SAST\u201d), we hereby declare that the Promoters or the Promoter Group have not made any encumbrance, directly or indirectly, on the shares \/ securities of the Company \u2018Piramal Pharma Limited\u2019 during the financial year 2025- 2026. You are requested to take note of the above. Thanking you, Yours faithfully For and on behalf of Promoter and Promoter Group Ajay G. Piramal\",\"category\":\"Disclosure under SEBI Takeover Regulations\",\"date\":\"29-Jun-2026 19:45:27\",\"source\":\"NSE corporate filing\",\"attachment\":\"https:\/\/nsearchives.nseindia.com\/corporate\/team_sandeshc_11052026115720_39.pdf\",\"detail_level\":\"pdf_facts\"}],\"source\":\"NSE corporate filing\"},\"shareholding_snapshot\":{\"promoter_pct\":34.8,\"public_pct\":64.8,\"fii_pct\":13.65,\"dii_pct\":14.44,\"mf_pct\":12.71,\"institutional_pct\":28.09,\"noninst_pct\":36.71,\"mf_scheme_count\":27,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund\",\"shares\":75248994,\"pct\":5.65},{\"name\":\"Nippon Life India Trustee Ltd-A\/C Nippon India Small Cap Fund\",\"shares\":20758801,\"pct\":1.56}],\"period\":\"30-SEP-2026\",\"submission_date\":\"21-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742857_21102026032628_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":34.8,\"previous_fii_pct\":12.52,\"previous_dii_pct\":14.57,\"previous_mf_pct\":13.18,\"previous_institutional_pct\":27.09,\"previous_mf_scheme_count\":25,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null}} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Piramal Pharma has risen 16.04% over 2 trading sessions. Today it is 0.95% lower at \u20b9230.60. See price context, volume and key company developments.<\/p>\n","protected":false},"author":1,"featured_media":9713,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Piramal Pharma Share Price Today: Rises 16.04% in 2 Trading Sessions | 29 October 2026","_witty_meta_description":"Piramal Pharma has risen 16.04% over 2 trading sessions. Today it is 0.95% lower at \u20b9230.60. See price context, volume and key company developments.","_witty_primary_phrase":"Piramal Pharma share price today","_witty_reason_label":"profit-taking and consolidation after strong multi-day rally","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[322],"class_list":["post-9714","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-pplpharma"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=9714"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9714\/revisions"}],"predecessor-version":[{"id":9715,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9714\/revisions\/9715"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/9713"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=9714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=9714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=9714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}